Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia.
Childhood Langerhans Cell Histiocytosis
Multiple Myeloma and Plasma Cell Neoplasm
Procedure: umbilical cord blood transplantation
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Transplantation Using Umbilical Cord And Placental Blood|
- Response rate [ Designated as safety issue: No ]
- Toxicity [ Designated as safety issue: Yes ]
- Survival [ Designated as safety issue: No ]
- Incidence of graft-versus-host disease [ Designated as safety issue: No ]
|Study Start Date:||January 1997|
- Determine the response rate of patients with chronic myeloid leukemia, acute leukemia, lymphoma, myeloma, myelodysplasia, aplastic anemia, Fanconi's anemia, histiocytosis, hereditary immunodeficiency, or storage disorder treated with allogeneic umbilical cord and placental blood transplantation.
- Determine the toxicity of this regimen in these patients.
- Determine survival in these patients treated with this regimen.
- Determine the incidence of graft-versus-host disease in these patients treated with this regimen.
OUTLINE: Patients receive a standard preparative regimen for their disease. Following the preparative regimen patients undergo umbilical cord blood stem cell transplantation on day 0.
Patients are followed every 1-2 weeks for 6 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 4-5 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00008164
|United States, New York|
|Herbert Irving Comprehensive Cancer Center at Columbia University|
|New York, New York, United States, 10032|
|Study Chair:||David G. Savage, MD||Herbert Irving Comprehensive Cancer Center|